Eris Lifesciences Complete Financial Statements
12 Years of Data
2026 - 2015
In FY2026, Eris Lifesciences (ERIS) reported revenue ₹755 Cr, net profit ₹279 Cr and EPS ₹20.60, with a net profit margin of 37.0% and ROE of 7.1%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Review ERIS PE ratio trends to evaluate earnings-based valuation against sector peers.
Complete Financial Data Export
Profitability Ratios
Net Profit Margin
36.95%
2026 data
EBITDA Margin
35.76%
2026 data
Operating Margin
36.00%
2026 data
Return on Assets
3.79%
2026 data
Return on Equity
7.15%
2026 data
Balance Sheet Ratios
Current Ratio
1.11
2026 data
Equity Ratio
52.99%
2026 data
Asset Turnover
0.10
2026 data
ERIS Revenue, Net Profit & EBITDA — Year-on-Year Growth
ERIS YoY (Mar 2025 vs Mar 2026) — revenue +6.2%, net profit +173.5%, EBITDA +4.7%, expenses +6.8%. Explore Eris Lifesciences intrinsic worth to estimate fundamental worth using multiple valuation models.
Revenue Growth
+6.2%
Year-over-Year
Net Profit Growth
+173.5%
Year-over-Year
EBITDA Growth
+4.7%
Year-over-Year
Expense Growth
+6.8%
Year-over-Year
Assets Growth
+4.7%
Year-over-Year
Equity Growth
+19.3%
Year-over-Year
Operating Cash Flow Growth
+119.1%
Year-over-Year
Investing Cash Flow Growth
+95.7%
Year-over-Year
Financing Cash Flow Growth
-163.8%
Year-over-Year
ERIS Income Statement — Revenue, EBITDA & Net Profit
Eris Lifesciences revenue ₹755 Cr, EBITDA ₹270 Cr, net profit ₹279 Cr, EPS ₹20.60 (2026) — net profit margin 37.0%. For live price, earnings ratios and company overview, see ERIS share price screener.
Periods
₹ Crores
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 | Sept 2021 | Mar 2021 | Jun 2021 | Dec 2021 | Sept 2020 | Mar 2020 | Jun 2020 | Dec 2020 | Sept 2019 | Mar 2019 | Jun 2019 | Dec 2019 | Sept 2018 | Mar 2018 | Jun 2018 | Dec 2018 | Sept 2017 | Mar 2017 | Jun 2017 | Dec 2017 | Sept 2016 | Jun 2016 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 755 | 793 | 711 | 775 | 801 | 744 | 562 | 717 | 726 | 504 | 398 | 461 | 488 | 461 | 309 | 395 | 420 | 360 | 277 | 350 | 333 | 327 | 243 | 289 | 308 | 286 | 223 | 275 | 270 | 267 | 215 | 251 | 259 | 237 | 189 | 192 | 213 | 208 | 188 | 190 |
| Expenses | 484 | 504 | 453 | 496 | 543 | 477 | 403 | 470 | 477 | 324 | 284 | 297 | 311 | 309 | 209 | 269 | 286 | 220 | 184 | 223 | 210 | 205 | 171 | 189 | 203 | 175 | 153 | 170 | 190 | 164 | 141 | 162 | 159 | 152 | 135 | 114 | 128 | 125 | 109 | 112 |
| EBITDA | 270 | 289 | 258 | 279 | 258 | 267 | 160 | 248 | 249 | 180 | 114 | 164 | 177 | 151 | 100 | 125 | 134 | 141 | 93 | 127 | 123 | 122 | 72 | 100 | 105 | 111 | 70 | 105 | 81 | 103 | 75 | 88 | 100 | 86 | 54 | 78 | 85 | 83 | 79 | 78 |
| Operating Profit Margin % | 36.00% | 36.00% | 36.00% | 36.00% | 32.00% | 35.00% | 26.00% | 34.00% | 34.00% | 35.00% | 28.00% | 35.00% | 36.00% | 32.00% | 31.00% | 31.00% | 32.00% | 38.00% | 33.00% | 35.00% | 36.00% | 37.00% | 30.00% | 34.00% | 33.00% | 38.00% | 28.00% | 38.00% | 28.00% | 37.00% | 32.00% | 34.00% | 36.00% | 34.00% | 27.00% | 39.00% | 38.00% | 37.00% | 40.00% | 39.00% |
| Depreciation | 70 | 69 | 77 | 71 | 70 | 81 | 54 | 76 | 81 | 42 | 35 | 41 | 46 | 29 | 18 | 23 | 30 | 15 | 12 | 15 | 17 | 11 | 14 | 10 | 11 | 12 | 11 | 12 | 13 | 8 | 9 | 7 | 10 | 5 | 7 | 5 | 7 | 5 | 5 | 6 |
| Interest | 46 | 50 | 54 | 49 | 49 | 60 | 33 | 60 | 57 | 16 | 9 | 17 | 18 | 7 | 1 | 7 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 4 | 1 | 0 | 6 | 8 | 7 | 5 | 0 | 0 | 0 | 3 | 1 | 0 | 0 |
| Profit Before Tax | 159 | 173 | 129 | 161 | 145 | 129 | 77 | 116 | 116 | 126 | 76 | 113 | 116 | 121 | 85 | 101 | 107 | 131 | 85 | 117 | 109 | 116 | 62 | 95 | 99 | 103 | 58 | 95 | 72 | 92 | 62 | 78 | 89 | 99 | 48 | 74 | 77 | 78 | 73 | 72 |
| Tax | -120 | 38 | 27 | 36 | 37 | 33 | -3 | 26 | 29 | 4 | 14 | 19 | 14 | 2 | 5 | 8 | 6 | 12 | 17 | 10 | 8 | 8 | 5 | 6 | 9 | 10 | 4 | 11 | 9 | 7 | 6 | 6 | 9 | 6 | 1 | 3 | 3 | 8 | 11 | 4 |
| Net Profit | 279 | 135 | 102 | 125 | 109 | 96 | 80 | 90 | 87 | 122 | 62 | 94 | 102 | 119 | 80 | 93 | 100 | 118 | 68 | 107 | 101 | 108 | 56 | 89 | 90 | 93 | 54 | 84 | 64 | 86 | 56 | 72 | 80 | 93 | 47 | 71 | 75 | 69 | 63 | 68 |
| Earnings Per Share (₹) | 20.60 | 8.82 | 6.90 | 8.66 | 7.32 | 6.73 | 5.22 | 6.11 | 6.16 | 9.08 | 4.81 | 6.97 | 7.55 | 8.84 | 5.91 | 6.96 | 7.49 | 8.71 | 5.03 | 7.86 | 7.41 | 7.93 | 4.13 | 6.56 | 6.64 | 6.74 | 3.93 | 6.11 | 4.62 | 6.20 | 4.06 | 5.18 | 5.83 | 6.75 | 3.43 | 5.15 | 5.43 | 5.02 | 45.64 | 4.95 |
ERIS Balance Sheet — Assets, Liabilities & Shareholders' Equity
ERIS total assets ₹7,366 Cr, total equity ₹3,903 Cr, total liabilities ₹ Cr (2026) — ROE 7.1%.
Years
Annual Data
₹ Crores
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Total Assets | 7,366 | 7,033 | 7,041 | 3,667 | 2,272 | 1,835 | 1,552 | 1,554 | 1,460 | 727 | 398 |
| Current Assets | 1,540 | 1,223 | 2,302 | 765 | 627 | 467 | 480 | 582 | 299 | 216 | 237 |
| Fixed Assets | 4,447 | 5,307 | 4,319 | 2,568 | 918 | 854 | 875 | 761 | 771 | 232 | 65 |
| Capital Work in Progress | 172 | 67 | 20 | 22 | 27 | 2 | 4 | 3 | 0 | 0 | 0 |
| Investments | 437 | 67 | 16 | 37 | 520 | 294 | 78 | 356 | 365 | 303 | 144 |
| Other Assets | 0 | 1,593 | 2,686 | 1,041 | 807 | 685 | 595 | 435 | 324 | 192 | 190 |
| LIABILITIES | |||||||||||
| Total Liabilities | |||||||||||
| Current Liabilities | 1,393 | 2,380 | 1,286 | 1,003 | 164 | 91 | 91 | 79 | 349 | 60 | 25 |
| Non-Current Liabilities | |||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||
| Total Equity | 3,903 | 3,272 | 3,222 | 2,221 | 1,908 | 1,576 | 1,296 | 1,169 | 886 | 591 | 302 |
| Share Capital | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 0 |
| Reserves & Surplus | 3,889 | 2,841 | 2,573 | 2,182 | 1,894 | 1,563 | 1,283 | 1,137 | 848 | 553 | 302 |
ERIS Cash Flow Statement — Operating, Investing & Financing
Eris Lifesciences operating cash flow ₹1,065 Cr, investing ₹-78 Cr, financing ₹-881 Cr, net cash flow ₹106 Cr (2025).
Periods
₹ Crores
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,065 | 486 | 292 | 378 | 375 | 271 | 223 | 235 | 200 | 132 | 90 |
| Investing Activities | -78 | -1,828 | -975 | -320 | -323 | 123 | -5 | -590 | -185 | -44 | -92 |
| Financing Activities | -881 | 1,380 | 688 | -45 | -82 | -335 | -221 | 363 | -24 | -84 | 1 |
| Net Cash Flow | 106 | 38 | 5 | 14 | -30 | 60 | -3 | 8 | -8 | 4 | -2 |